Hims & Hers Health (NYSE:HIMS – Get Free Report) had its price objective increased by equities research analysts at Canaccord Genuity Group from $28.00 to $38.00 in a report released on ...

Dr. Lokesh, Associate Professor in the Department of General Medicine in the Hassan Institute of Medical Sciences, was ...

Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) shares were up 6.6% during trading on Tuesday after Canaccord Genuity Group raised their price target on the stock from $28.00 to $38.00.

Eleven cases of hypertrichosis — commonly known as “werewolf syndrome” — has developed in babies throughout Spain.

The American Diabetes Association is advising doctors and patients not to use compounded GLP-1s due to uncertainty about their content, safety, ...

Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, ...

Hims & Hers Health, Inc. (HIMS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of ...

The ADA recommended doctors avoid prescribing unapproved, off-brand versions of drugs like Wegovy, wading into a dispute that ...

Canaccord raised the firm’s price target on Hims & Hers to $38 from $28 and keeps a Buy rating on the shares. The stock rallied 70% in ...

The Washington Post: This Year, Be Thankful For AI In Medicine Artificial intelligence is revolutionizing medicine, making health care more accurate and less expensive for everyone. (11/27) ...

On Friday, Hims & Hers Health Inc (HIMS) stock saw a modest uptick, ending the day at $32.15 which represents a slight increase of $1.81 or 5.97% from the prior close of $30.34. The stock opened at ...

Everyone has a right to their own opinions. But we must ensure the antisemitic views of individuals are known to their ...